Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.11
CLVS's Cash to Debt is ranked lower than
70% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. CLVS: 2.11 )
Ranked among companies with meaningful Cash to Debt only.
CLVS' s Cash to Debt Range Over the Past 10 Years
Min: 0.91  Med: 10000.00 Max: No Debt
Current: 2.11
F-Score: 3
Z-Score: -0.34
M-Score: -4.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -90.84
CLVS's ROE (%) is ranked lower than
79% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. CLVS: -90.84 )
Ranked among companies with meaningful ROE (%) only.
CLVS' s ROE (%) Range Over the Past 10 Years
Min: -144.26  Med: -47.18 Max: -26.78
Current: -90.84
-144.26
-26.78
ROA (%) -37.17
CLVS's ROA (%) is ranked lower than
59% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. CLVS: -37.17 )
Ranked among companies with meaningful ROA (%) only.
CLVS' s ROA (%) Range Over the Past 10 Years
Min: -65.51  Med: -36.71 Max: -21.25
Current: -37.17
-65.51
-21.25
ROC (Joel Greenblatt) (%) -9040.73
CLVS's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. CLVS: -9040.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CLVS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8446.45  Med: -7022.22 Max: -4951.81
Current: -9040.73
-8446.45
-4951.81
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

CLVS Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

CLVS Guru Trades in Q1 2015

Steven Cohen 100,000 sh (unchged)
» More
Q2 2015

CLVS Guru Trades in Q2 2015

Steven Cohen 117,100 sh (unchged)
» More
Q3 2015

CLVS Guru Trades in Q3 2015

Jim Simons 128,900 sh (New)
Andreas Halvorsen 836,332 sh (New)
Paul Tudor Jones 4,131 sh (New)
Steven Cohen 117,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.75
CLVS's P/B is ranked higher than
67% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. CLVS: 1.75 )
Ranked among companies with meaningful P/B only.
CLVS' s P/B Range Over the Past 10 Years
Min: 1.74  Med: 5.73 Max: 11.72
Current: 1.75
1.74
11.72
Current Ratio 8.10
CLVS's Current Ratio is ranked higher than
69% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. CLVS: 8.10 )
Ranked among companies with meaningful Current Ratio only.
CLVS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 11.63 Max: 31.09
Current: 8.1
0.86
31.09
Quick Ratio 8.10
CLVS's Quick Ratio is ranked higher than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CLVS: 8.10 )
Ranked among companies with meaningful Quick Ratio only.
CLVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 11.63 Max: 31.09
Current: 8.1
0.86
31.09

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.65
CLVS's Price/Net Cash is ranked higher than
50% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. CLVS: 5.65 )
Ranked among companies with meaningful Price/Net Cash only.
CLVS' s Price/Net Cash Range Over the Past 10 Years
Min: 2.45  Med: 5.99 Max: 67.47
Current: 5.65
2.45
67.47
Price/Net Current Asset Value 5.26
CLVS's Price/Net Current Asset Value is ranked lower than
51% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CLVS: 5.26 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CLVS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.43  Med: 5.96 Max: 51.85
Current: 5.26
2.43
51.85
Price/Tangible Book 4.63
CLVS's Price/Tangible Book is ranked lower than
56% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CLVS: 4.63 )
Ranked among companies with meaningful Price/Tangible Book only.
CLVS' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.39  Med: 6.27 Max: 390.68
Current: 4.63
2.39
390.68
Price/Graham Number 1.19
CLVS's Price/Graham Number is ranked higher than
69% of the 407 Companies
in the Global Biotechnology industry.

( Industry Median: 2.23 vs. CLVS: 1.19 )
Ranked among companies with meaningful Price/Graham Number only.
CLVS' s Price/Graham Number Range Over the Past 10 Years
Min: 5.52  Med: 5.52 Max: 5.52
Current: 1.19
Earnings Yield (Greenblatt) (%) -71.25
CLVS's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. CLVS: -71.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CLVS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -70.97  Med: 0.00 Max: 0
Current: -71.25
-70.97
0

More Statistics

Revenue(Mil) $14
EPS $ -8.20
Beta1.68
Short Percentage of Float31.12%
52-Week Range $17.76 - 116.75
Shares Outstanding(Mil)38.32

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
Kyle Bass Builds Bull Case for Clovis Oncology Nov 27 2015 
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 

More From Other Websites
Biotechnology Equities Technical Commentary -- Relypsa, PDL BioPharma, Pacific Biosciences of... Feb 09 2016
Clovis (CLVS) Begins Immunotherapy Combination Study Jan 28 2016
Clovis Oncology Initiates Immunotherapy Combination Trial Jan 27 2016
Clovis Oncology Initiates Immunotherapy Combination Trial Jan 27 2016
Clovis Oncology replaces key executive Jan 25 2016
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 25 2016
Clovis Oncology Appoints Dale Hooks as Chief Commercial Officer Jan 25 2016
Clovis Oncology Appoints Dale Hooks as Chief Commercial Officer Jan 25 2016
Coverage initiated on Clovis Oncology by Credit Suisse Jan 21 2016
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against... Jan 19 2016
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Clovis Oncology, Inc. of Filing of... Jan 18 2016
SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Clovis Oncology,... Jan 15 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Clovis Oncology, Inc. of Filing of... Jan 14 2016
Kessler Topaz Meltzer & Check, LLP Reminds Clovis Oncology, Inc. Shareholders of January 19, 2016... Jan 14 2016
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against... Jan 13 2016
UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000... Jan 12 2016
INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Clovis... Jan 12 2016
Lifshitz & Miller Law Firm Announces Investigation of Chipotle Mexican Grill, Inc., Clovis Oncology,... Jan 08 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Clovis Oncology, Inc. of Filing of... Jan 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK